Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC)
Open Access
- 8 February 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1122529
- https://doi.org/10.3389/fmed.2023.1122529
Abstract
Post-acute sequelae of COVID (PASC), or long COVID, is a multisystem complication of SARS-CoV-2 infection that continues to debilitate millions worldwide thus highlighting the public health importance of identifying effective therapeutics to alleviate this illness. One explanation behind PASC may be attributed to the recent discovery of persistent S1 protein subunit of SARS-CoV-2 in CD16+ monocytes up to 15 months after infection. CD16+ monocytes, which express both CCR5 and fractalkine receptors (CX3CR1), play a role in vascular homeostasis and endothelial immune surveillance. We propose targeting these receptors using the CCR5 antagonist, maraviroc, along with pravastatin, a fractalkine inhibitor, could disrupt the monocytic-endothelial-platelet axis that may be central to the etiology of PASC. Using five validated clinical scales (NYHA, MRC Dyspnea, COMPASS-31, modified Rankin, and Fatigue Severity Score) to measure 18 participants’ response to treatment, we observed significant clinical improvement in six to twelve weeks on a combination of maraviroc 300mg per oral twice a day and pravastatin 10 mg per oral daily. Subjective neurological, autonomic, respiratory, cardiac and fatigue symptoms scores all decreased which correlated with statistically significant decreases in vascular markers sCD40L and VEGF. These findings suggest that by interrupting the monocytic-endothelial-platelet axis, maraviroc and pravastatin may restore the immune dysregulation observed in PASC and could be potential therapeutic options. This sets the framework for a future double-blinded, placebo-controlled randomized trial to further investigate the drug efficacy of maraviroc and pravastatin in treating PASC.This publication has 43 references indexed in Scilit:
- Efficacy of the CCR5 Antagonist Maraviroc in Reducing Early, Ritonavir-Induced Atherogenesis and Advanced Plaque Progression in MiceJournal of the American College of Cardiology, 2013
- COMPASS 31: A Refined and Abbreviated Composite Autonomic Symptom ScoreMayo Clinic Proceedings, 2012
- In vitro effects of the CCR5 inhibitor maraviroc on human T cell functionJournal of Antimicrobial Chemotherapy, 2012
- Hepatic safety and tolerability in the maraviroc clinical development programAIDS, 2010
- Cell Adhesion Mechanisms in PlateletsArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndromeJournal of Thrombosis and Haemostasis, 2006
- Chemokine receptor CCR5: insights into structure, function, and regulationCellular Signalling, 2004
- Soluble CD40 Ligand in Pulmonary Arterial HypertensionJournal of the American College of Cardiology, 2004
- Endothelial Cells Are Main Producers of Interleukin 8 through Toll-Like Receptor 2 and 4 Signaling during Bacterial Infection in Leukopenic Cancer PatientsClinical and Vaccine Immunology, 2003
- R: A Language for Data Analysis and GraphicsJournal of Computational and Graphical Statistics, 1996